GlassScriptPhysician profile
Luther Burse
NPI 1366441438
$4,471.02
in general payments reported to CMS, 2019-2025
24 companies · $701 in 2025
The $701 reported for 2025 was more than what 84% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $697 · 2020: $382 · 2021: $944 · 2022: $603 · 2023: $446 · 2024: $698 · 2025: $701.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,846.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,845.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,973.99 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $717.66 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Janssen Biotech, INC. | $438.19 | 2019-2025 | Tremfya, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $201.61 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $119.99 | 2022-2023 | |
| Gilead Sciences, INC. | $98.86 | 2019-2022 | |
| Madrigal Pharmaceuticals | $90.16 | 2024-2025 | Resmetirom, Rezdiffra |
| Ferring Pharmaceuticals INC. | $84.49 | 2019 | |
| Phathom Pharmaceuticals, INC. | $81.95 | 2024-2025 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $80.89 | 2023 | Dupixent |
| Celgene Corporation | $74.90 | 2022-2023 | Zeposia |
| Braintree Laboratories, INC. | $66.66 | 2021-2023 | Sutab |
| Redhill Biopharma INC. | $65.52 | 2020-2021 | |
| Ironwood Pharmaceuticals, INC | $61.38 | 2019-2023 | Linzess |
| Allergan, INC. | $42.83 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $42.41 | 2019 | |
| Intercept Pharmaceuticals, INC. | $41.38 | 2019-2020 | |
| Novo Nordisk INC | $40.43 | 2023-2025 | Wegovy |
| Exact Sciences Corporation | $37.62 | 2023 | Cologuard Collection Kit |
| Medtronic, INC. | $36.29 | 2024 | Interstim |
| Alfasigma USA, INC. | $22.56 | 2020 | |
| Aimmune Therapeutics, INC. | $19.27 | 2025 | Zenpep |
| Intra-Sana Laboratories | $16.17 | 2021 | |
| Ucb, INC. | $15.81 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luther Burse listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.